Pneumatic displacement of submacular hemorrhage

Current Opinion in Ophthalmology

Volumn 11, Issue 3, 2000, Pages 201-206

  Johnson, Mark W ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; PATIENT POSITIONING; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

GASES; HUMANS; INJECTIONS; MACULA LUTEA; MACULAR DEGENERATION; PLASMINOGEN ACTIVATORS; POSTURE; RETINAL HEMORRHAGE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 0034121911     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200006000-00009     Document Type: Article

References (35)

1. 1 Bennett SR, Folk JC, Blodi CF, Klugman M: Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990, 109: 33-37.
2. 2 Berrocal MH, Lewis ML, Flynn HW: Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol 1996, 122:486-493.
3. 3 Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996, 16: 183-189.
4. 4 Scupola A, Coscas G, Soubrane G, Balestrazzi E: Natural history of subretinal hemorrhage in age-related macular degeneration. Ophthalmologicsa 1999, 213:97-102.
5. 5 Glatt H, Machemer R: Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982, 94:762-773.
6. 6 Toth CA, Morse LS, Hjelmeland LM, Landers MB III: Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991, 109:723-729.
7. 7 Johnson MW, Olsen KR, Hernandez E: Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Retina 1991, 11:250-258.
8. 8 Benner JD, Morse LS, Toth CA, et al.: Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. Arch Ophthalmol 1991, 109:1731-1736.
9. 9 Boone DE, Boldt HC, Ross RD, et al.: The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model. Retina 1996, 16:518-524.
10. 10 Coll GE, Sparrow JR, Marinovic A, Chang S: Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995, 15: 319-326.
11. 11 Johnson MW, Olsen KR, Hernandez E: Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage. Ophthalmology 1992, 99:515-521.
12. 12 Lewis H, Resnick SC, Flannery JG, Straatsma BR: Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol 1991, 111:197-204.
13. 13 Lewis H: Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994, 118: 559-568.
14. 14 Ibanez HE, Williams DF, Thomas MA, et al.: Surgical management of submacular hemorrhage: a series of 47 consecutive cases. Arch Ophthalmol 1995, 113:62-69.
15. 15 Lim JI, Drews-Botsch C, Sternberg P Jr, et al.: Submacular hemorrhage removal. Ophthalmology 1995, 102:1393-1399.
16. 16 Moriarty AP, McAllister IL, Constable IJ: Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage. Eye 1995, 9:582-588.
17. 17 Kamei M, Tano Y, Maeno T, et al.: Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol 1996, 121:267-275.
18. 18 Hesse L, Meitinger D, Schmidt J: Little effect of tissue plasminogen activator in subretinal surgery for acute hemorrhage in age-related macular degeneration. Ger J Ophthalmol 1997, 5:479-483.
19. 19 Claes C, Zivojnovic R: Efficacy of tissue plasminogen activator (T-PA) in subretinal hemorrhage removal. Bull Soc Belge Ophtalmol 1996, 261:115-118.
20. 20 Hassan AS, Johnson MW, Schneiderman TE, et al.: Management of submacular hemorrhage with intravitreous tPA injection and pneumatic displacement. Ophthalmology 1999, 106:1900-1907. This multicenter, retrospective, noncomparative case series demonstrates that intravitreous injection of tPA and gas followed by brief prone positioning is effective in displacement of thick blood in the foveal area, facilitating visual improvement. The complication rate appears acceptably low.
21. 21 Hesse L, Schmidt J, Kroll P: Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefe's Arch Clin Exp Ophthalmol 1999, 237:273-277. Intravitreal tPA causes liquefaction of submacular blood clots in the macula that can be displaced with intravitreal gas and face-down positioning. Retinal toxic effects were seen in eyes treated with 100 μg tPA, but not in eyes receiving 50 μg.
22. 22 Karlsson E, Carlsson JO, Crofoord S, et al.: Tissue plasminogen activator and expanding gas intravitreally in treatment of submacular hemorrhage. Acta Ophthalmol Scand 1999, 77:119.
23. 23 Meier P, Zeumer C, Jochmann C, Wiedemann P: Management of submacular hemorrhage by tissue plasminogen activator and SF6 gas injection. Ophthalmologue 1999, 96:643-647.
24. 24 Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y: Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998, 116:1326-1332. Intravitreal injection of gas without tPA, followed by prone positioning, is effective in displacing submacular blood in 60% of eyes in this small series.
25. 25 Shiraga F, Matsuo T, Yokoe S, et al.: Surgical treatment of submacular hemorrhage associated with polypoidal choroidal vasculopathy. Am J Ophthalmol 1999, 128:147-154.
26. 26 Hrach CJ, Johnson MW, Hassan AS, et al.: Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in the cat eye. Arch Ophthalmol 2000, in press.
27. 27 Ohji M, Marino S, Saito Y, et al.: Vitreous hemorrhage after intravitreal gas injection in patients with submacular hemorrhage [abstract]. Invest Ophthalmol Vis Sci 1999, 409(suppl):S319.
28. 28 Sternberg P Jr, Aguilar HE, Drews C, Aaberg TM: The effect of tissue plasminogen activator on retinal bleeding. Arch Ophthalmol 1990, 108:720-722.
29. 29 Kamei M, Misono K, Lewis H: A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 1999, 128:739-746. Labeled tPA injected into the vitreous of rabbit eyes with experimental subretinal hemorrhage did not diffuse through the retina in the absence of vitreous hemorrhage.
30. 30 Takeuchi A, Kricorian G, Yao XY, et al.: The rate and source of albumin entry into saline-filled experimental retinal detachments. Invest Ophthalmol Vis Sci 1994, 35:3792-3598.
31. 31 Kimura AE, Reddy CV, Folk JC, Farmer SG: Removal of subretinal hemorrhage facilitated by preoperative intravitreal tissue plasminogen activator. Retina 1994, 14:83-84.
32. 32 Egana BC, Lapuente CR, Peyman GA: Intravitreal distribution of tissue plasminogen activator in nonvitrectomized and fibrin-filled vitrectomized eyes [abstract]. Invest Ophthalmol Vis Sci 1997, 38(suppl):S212.
33. 33 Johnson MW, Olsen KR, Hernandez E, et al.: Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990, 108:259-263.
34. 34 LaPuente CJR, Peyman GA, Castilla MR, et al.: Retinal toxicity of intravitreal injection of tissue plasminogen activator in nonvitrectomized eyes [abstract]. Invest Ophthalmol Vis Sci 1998, 399(suppl):S988.
35. 35 Zemel E, Loewenstein A, Lei B, et al.: Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity. Invest Ophthalmol Vis Sci 1995, 36: 1875-1884.